TY - JOUR
T1 - Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis
AU - Hamadani, Mehdi
AU - Kanate, Abraham S.
AU - DiGilio, Alyssa
AU - Ahn, Kwang Woo
AU - Smith, Sonali M.
AU - Lee, Jong Wook
AU - Ayala, Ernesto
AU - Chao, Nelson
AU - Hari, Parameswaran
AU - Bolaños-Meade, Javier
AU - Gress, Ronald
AU - Smedegaard Anderson, Niels
AU - Chen, Yi Bin
AU - Farooq, Umar
AU - Schiller, Gary
AU - Yared, Jean
AU - Sureda, Anna
AU - Fenske, Timothy S.
AU - Olteanu, Horatiu
N1 - Publisher Copyright:
© 2017 The American Society for Blood and Marrow Transplantation
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Aggressive NK cell leukemia (ANKL) is an exceedingly rare form of leukemia and carries a poor prognosis, with a median survival of only 2 months. Using the Center for International Blood and Marrow Transplant Research database, we evaluated outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in patients with ANKL. Twenty-one patients with a centrally confirmed diagnosis of ANKL were included. Median patient age was 42 years and 15 patients (71%) were Caucasian. Fourteen patients (67%) were in complete remission (CR) at the time of alloHCT, and 5 patients had active disease. Median follow-up of survivors was 25 months (range, 12 to 116). The 2-year estimates of nonrelapse mortality, relapse/progression, progression-free (PFS), and overall survival (OS) were 21%, 59%, 20%, and 24%, respectively. The 2-year PFS of patients in CR at the time of alloHCT was significantly better than that of patients with active disease at transplantation (30% versus 0%; P = .001). The 2-year OS in similar order was 38% versus 0% (P < .001). In conclusion, this registry analysis that included majority non-Asian patient population shows that alloHCT can provide durable disease control in a subset of ANKL patients. Achieving CR before transplantation appears to be a prerequisite for successful transplantation outcomes.
AB - Aggressive NK cell leukemia (ANKL) is an exceedingly rare form of leukemia and carries a poor prognosis, with a median survival of only 2 months. Using the Center for International Blood and Marrow Transplant Research database, we evaluated outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in patients with ANKL. Twenty-one patients with a centrally confirmed diagnosis of ANKL were included. Median patient age was 42 years and 15 patients (71%) were Caucasian. Fourteen patients (67%) were in complete remission (CR) at the time of alloHCT, and 5 patients had active disease. Median follow-up of survivors was 25 months (range, 12 to 116). The 2-year estimates of nonrelapse mortality, relapse/progression, progression-free (PFS), and overall survival (OS) were 21%, 59%, 20%, and 24%, respectively. The 2-year PFS of patients in CR at the time of alloHCT was significantly better than that of patients with active disease at transplantation (30% versus 0%; P = .001). The 2-year OS in similar order was 38% versus 0% (P < .001). In conclusion, this registry analysis that included majority non-Asian patient population shows that alloHCT can provide durable disease control in a subset of ANKL patients. Achieving CR before transplantation appears to be a prerequisite for successful transplantation outcomes.
KW - Aggressive natural killer cell leukemia
KW - Allogeneic transplantation
KW - Myeloablative
KW - Reduced-intensity conditioning
UR - http://www.scopus.com/inward/record.url?scp=85013473580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013473580&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2017.01.082
DO - 10.1016/j.bbmt.2017.01.082
M3 - Article
C2 - 28161608
AN - SCOPUS:85013473580
SN - 1083-8791
VL - 23
SP - 853
EP - 856
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 5
ER -